|
May 13
|
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
May 10
|
RxSight, Inc. (NASDAQ:RXST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$72.75
|
|
May 9
|
RxSight First Quarter 2024 Earnings: Beats Expectations
|
|
May 9
|
RxSight, Inc. Announces Pricing of Public Offering of Common Stock
|
|
May 8
|
RxSight, Inc. Announces Proposed Public Offering of Common Stock
|
|
May 7
|
RxSight, Inc. (NASDAQ:RXST) Q1 2024 Earnings Call Transcript
|
|
May 7
|
Q1 2024 Rxsight Inc Earnings Call
|
|
May 7
|
RxSight Inc (RXST) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
|
|
May 6
|
RxSight Inc (RXST) Surpasses Analyst Revenue Forecasts in Q1 2024
|
|
May 6
|
RxSight, Inc. Reports First Quarter 2024 Financial Results
|
|
May 1
|
RxSight, Inc. to Present at the Bank of America Healthcare Conference
|
|
Apr 25
|
Should You Investigate RxSight, Inc. (NASDAQ:RXST) At US$52.84?
|
|
Apr 22
|
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
|
|
Apr 4
|
RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
|
|
Mar 27
|
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
|
Jan 12
|
Strength Seen in Integer (ITGR): Can Its 3.8% Jump Turn into More Strength?
|
|
Jan 9
|
RxSight, Inc. (RXST) Just Overtook the 20-Day Moving Average
|
|
Jan 7
|
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance
|
|
Nov 15
|
RxSight, Inc. (RXST) Recently Broke Out Above the 50-Day Moving Average
|
|
Sep 7
|
RxSight, Inc. (RXST) Crossed Above the 20-Day Moving Average: What That Means for Investors
|